Complexity of response evaluation during primary systemic therapy of breast cancer: Scoring systems and beyond-preliminary results

Tímea Tokés, Gyöngyvér Szentmártoni, László Torgyík, Krisztián Somlai, J. Kulka, Z. Lengyel, Tamás Györke, Magdolna Dank

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Precise and standardized response evaluation enables clinicians to tailor primary systemic therapy (PST). Patients and Methods: Breast cancer patients underwent 18F-fluoro-deoxy-glucose positron emission tomography and computerized tomography (FDG-PET/CT) before and after PST. Response was assessed by maximal Standardized Uptake Value (SUVmax); morphological changes and Ki-67 labeling index (LI). In parallel response assessment was performed by European Organization for Research and Treatment of Cancer (EORTC); PET Response Criteria in Solid Tumors (PERCIST); World Health Organization (WHO); Response Evaluation Criteria in Solid Tumors (RECIST); Chevallier and Sataloff classifications, and by a novel Ki-67 score. Accuracy of different scoring systems was evaluated. Results: In the 42 enrolled patients, SUVmax, size, and Ki-67 LI decreased significantly on PST. Significant differences between patients with versus those without pathological complete response were observed for pre-treatment Ki-67 LI and SUVmax and for post-treatment Ki-67 LI, SUVmax and size. Change in Ki-67 LI was the best predictor of pathological complete response. Correlation patterns of the directly measured metabolic, morphological, and proliferation responses differed from those determined by scoring methods. Conclusion: During PST, FDG-PET/CT enables for robust assessment of treatment efficacy, but more reliable scoring systems are still needed for more precise response evaluation.

Original languageEnglish
Pages (from-to)5063-5072
Number of pages10
JournalAnticancer Research
Volume35
Issue number9
Publication statusPublished - Sep 1 2015

Fingerprint

Breast Neoplasms
Positron-Emission Tomography
Therapeutics
Tomography
Glucose
Neoplasms
Research Design
Organizations
Research

Keywords

  • Breast cancer
  • FDG-PET/CT
  • Ki-67
  • Primary systemic therapy
  • Response evaluation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Complexity of response evaluation during primary systemic therapy of breast cancer : Scoring systems and beyond-preliminary results. / Tokés, Tímea; Szentmártoni, Gyöngyvér; Torgyík, László; Somlai, Krisztián; Kulka, J.; Lengyel, Z.; Györke, Tamás; Dank, Magdolna.

In: Anticancer Research, Vol. 35, No. 9, 01.09.2015, p. 5063-5072.

Research output: Contribution to journalArticle

Tokés, T, Szentmártoni, G, Torgyík, L, Somlai, K, Kulka, J, Lengyel, Z, Györke, T & Dank, M 2015, 'Complexity of response evaluation during primary systemic therapy of breast cancer: Scoring systems and beyond-preliminary results', Anticancer Research, vol. 35, no. 9, pp. 5063-5072.
Tokés, Tímea ; Szentmártoni, Gyöngyvér ; Torgyík, László ; Somlai, Krisztián ; Kulka, J. ; Lengyel, Z. ; Györke, Tamás ; Dank, Magdolna. / Complexity of response evaluation during primary systemic therapy of breast cancer : Scoring systems and beyond-preliminary results. In: Anticancer Research. 2015 ; Vol. 35, No. 9. pp. 5063-5072.
@article{35b83ba1e8ba439c8edf3487d9c48c9d,
title = "Complexity of response evaluation during primary systemic therapy of breast cancer: Scoring systems and beyond-preliminary results",
abstract = "Background: Precise and standardized response evaluation enables clinicians to tailor primary systemic therapy (PST). Patients and Methods: Breast cancer patients underwent 18F-fluoro-deoxy-glucose positron emission tomography and computerized tomography (FDG-PET/CT) before and after PST. Response was assessed by maximal Standardized Uptake Value (SUVmax); morphological changes and Ki-67 labeling index (LI). In parallel response assessment was performed by European Organization for Research and Treatment of Cancer (EORTC); PET Response Criteria in Solid Tumors (PERCIST); World Health Organization (WHO); Response Evaluation Criteria in Solid Tumors (RECIST); Chevallier and Sataloff classifications, and by a novel Ki-67 score. Accuracy of different scoring systems was evaluated. Results: In the 42 enrolled patients, SUVmax, size, and Ki-67 LI decreased significantly on PST. Significant differences between patients with versus those without pathological complete response were observed for pre-treatment Ki-67 LI and SUVmax and for post-treatment Ki-67 LI, SUVmax and size. Change in Ki-67 LI was the best predictor of pathological complete response. Correlation patterns of the directly measured metabolic, morphological, and proliferation responses differed from those determined by scoring methods. Conclusion: During PST, FDG-PET/CT enables for robust assessment of treatment efficacy, but more reliable scoring systems are still needed for more precise response evaluation.",
keywords = "Breast cancer, FDG-PET/CT, Ki-67, Primary systemic therapy, Response evaluation",
author = "T{\'i}mea Tok{\'e}s and Gy{\"o}ngyv{\'e}r Szentm{\'a}rtoni and L{\'a}szl{\'o} Torgy{\'i}k and Kriszti{\'a}n Somlai and J. Kulka and Z. Lengyel and Tam{\'a}s Gy{\"o}rke and Magdolna Dank",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "35",
pages = "5063--5072",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Complexity of response evaluation during primary systemic therapy of breast cancer

T2 - Scoring systems and beyond-preliminary results

AU - Tokés, Tímea

AU - Szentmártoni, Gyöngyvér

AU - Torgyík, László

AU - Somlai, Krisztián

AU - Kulka, J.

AU - Lengyel, Z.

AU - Györke, Tamás

AU - Dank, Magdolna

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: Precise and standardized response evaluation enables clinicians to tailor primary systemic therapy (PST). Patients and Methods: Breast cancer patients underwent 18F-fluoro-deoxy-glucose positron emission tomography and computerized tomography (FDG-PET/CT) before and after PST. Response was assessed by maximal Standardized Uptake Value (SUVmax); morphological changes and Ki-67 labeling index (LI). In parallel response assessment was performed by European Organization for Research and Treatment of Cancer (EORTC); PET Response Criteria in Solid Tumors (PERCIST); World Health Organization (WHO); Response Evaluation Criteria in Solid Tumors (RECIST); Chevallier and Sataloff classifications, and by a novel Ki-67 score. Accuracy of different scoring systems was evaluated. Results: In the 42 enrolled patients, SUVmax, size, and Ki-67 LI decreased significantly on PST. Significant differences between patients with versus those without pathological complete response were observed for pre-treatment Ki-67 LI and SUVmax and for post-treatment Ki-67 LI, SUVmax and size. Change in Ki-67 LI was the best predictor of pathological complete response. Correlation patterns of the directly measured metabolic, morphological, and proliferation responses differed from those determined by scoring methods. Conclusion: During PST, FDG-PET/CT enables for robust assessment of treatment efficacy, but more reliable scoring systems are still needed for more precise response evaluation.

AB - Background: Precise and standardized response evaluation enables clinicians to tailor primary systemic therapy (PST). Patients and Methods: Breast cancer patients underwent 18F-fluoro-deoxy-glucose positron emission tomography and computerized tomography (FDG-PET/CT) before and after PST. Response was assessed by maximal Standardized Uptake Value (SUVmax); morphological changes and Ki-67 labeling index (LI). In parallel response assessment was performed by European Organization for Research and Treatment of Cancer (EORTC); PET Response Criteria in Solid Tumors (PERCIST); World Health Organization (WHO); Response Evaluation Criteria in Solid Tumors (RECIST); Chevallier and Sataloff classifications, and by a novel Ki-67 score. Accuracy of different scoring systems was evaluated. Results: In the 42 enrolled patients, SUVmax, size, and Ki-67 LI decreased significantly on PST. Significant differences between patients with versus those without pathological complete response were observed for pre-treatment Ki-67 LI and SUVmax and for post-treatment Ki-67 LI, SUVmax and size. Change in Ki-67 LI was the best predictor of pathological complete response. Correlation patterns of the directly measured metabolic, morphological, and proliferation responses differed from those determined by scoring methods. Conclusion: During PST, FDG-PET/CT enables for robust assessment of treatment efficacy, but more reliable scoring systems are still needed for more precise response evaluation.

KW - Breast cancer

KW - FDG-PET/CT

KW - Ki-67

KW - Primary systemic therapy

KW - Response evaluation

UR - http://www.scopus.com/inward/record.url?scp=84939616102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939616102&partnerID=8YFLogxK

M3 - Article

C2 - 26254408

AN - SCOPUS:84939616102

VL - 35

SP - 5063

EP - 5072

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -